Drugs / Carfilzomib
Carfilzomib
also known as
Kyprolis (carfilzomib) for Injection · Kyprolis · Carfilzomib - Kyprolis · CFZ · CAR · Carfilzomib Injection · Kyprolis (carfilzomib) · NSC-758252 · +1 more
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | KYPROLIS | — | 2015-07-24 – 2025-05-22 | fda.gov ↗ |
| Approved | EU (EMA) | Kyprolis | — | 2015-11-19 | europa.eu ↗ |
| Approved | US (FDA) | KYPROLIS | — | 2012-07-20 | fda.gov ↗ |
Trials 196 · started per year
today
US approved 2012
EU approved 2015
1
3
2
3
7
11
10
24
23
19
6
14
13
12
7
11
6
9
3
3
8
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 147 trials | ||||||
| Phase 1 | NCT06918990 | May 2026 → Jun 2027 expected | transplant rejection | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT06249282 | Apr 2024 → Nov 2026 expected | non-small cell lung carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05651932 | Feb 2023 → Dec 2027 expected | plasma cell myeloma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05675449 | Dec 2022 → Jul 2025 overdue | plasma cell myeloma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04895410 | Jan → Jun 2022 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT05050097 | Sep 2021 → Mar 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03909412 | Oct 2019 → Sep 2026 expected | plasma cell myeloma | Hackensack Meridian Health | Recruiting | No outcome recorded |
| Phase 1 | NCT03798678 | Jul 2019 → Nov 2023 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03605719 | Oct 2018 → Oct 2022 | plasma cell myeloma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT03530683 | May 2018 → Jul 2024 | acute myeloid leukemia, diffuse large B-cell lymphoma, plasma cell myeloma | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT03432741 | Mar 2018 → Aug 2022 | Hodgkins lymphoma, breast adenocarcinoma, mycosis fungoides, nodal marginal zone B-cell lymphoma | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT02512926 | Feb 2016 → Aug 2021 | leukemia, refractory malignant neoplasm | Stanford University | Completed | No outcome recorded |
| Phase 1 | NCT02293109 | Dec 2015 → Dec 2017 | adult acute lymphoblastic leukemia | Mehrdad Abedi, MD | Completed | No outcome recorded |
| Phase 1 | NCT02187133 | May 2015 → Mar 2021 | non-Hodgkin lymphoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT02335983 | Apr 2015 → Oct 2019 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02269085 | Apr 2015 → May 2018 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02303821 | Feb 2015 → Jun 2024 | acute lymphoblastic leukemia | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02332850 | Jan 2015 → Dec 2025 | plasma cell myeloma | Thomas Martin, MD | Completed | No outcome recorded |
| Phase 1 | NCT02101944 | Dec 2014 → May 2021 | anemia, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02442648 | Dec 2014 → Jun 2021 | — | E. Steve Woodle | Unknown | No outcome recorded |
| Phase 1 | NCT01991301 | Nov 2014 → Nov 2017 | graft versus host disease | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT02235740 | Nov 2014 → Oct 2015 | cancer | Novartis | Terminated | No outcome recorded |
| Phase 1 | NCT02142530 | Oct 2014 → Mar 2017 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02257476 | Aug 2014 → Nov 2016 | cancer | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01926665 | Jun 2014 → Sep 2017 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02199665 | Jun 2014 → Oct 2025 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT02095834 | Apr 2014 → Jan 2021 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01959698 | Apr 2014 → Jun 2020 overdue | diffuse large B-cell lymphoma | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01949532 | Jan 2014 → Apr 2015 | end stage renal failure, plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01949545 | Oct 2013 → Aug 2015 | cancer, hematopoietic and lymphoid cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01980589 | Aug 2013 → Mar 2016 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT01729104 | Apr 2013 → Oct 2018 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT01738594 | Mar 2013 → Oct 2016 | mycosis fungoides and variants, primary cutaneous T-cell non-Hodgkin lymphoma | Northwestern University | Terminated | No outcome recorded |
| Phase 1 | NCT01789242 | Feb 2013 → Dec 2016 | AL amyloidosis | Criterium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01660750 | Jan 2013 → Aug 2015 | plasma cell myeloma | Criterium, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01372540 | Feb 2012 → May 2019 | plasma cell leukemia, plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01549431 | Jan 2012 → Feb 2016 | plasma cell myeloma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01301807 | Jul 2011 → Nov 2019 | non-secretory plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01336920 | Jun 2011 → Apr 2015 | adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal nasal NK/T cell lymphoma +1 | University of Nebraska | Completed | No outcome recorded |
| Phase 1 | NCT01276717 | Jan 2011 → Jul 2013 | lymphoma | University of Rochester | Completed | No outcome recorded |
| Phase 1 | NCT01137747 | Oct 2010 → Aug 2014 | leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01212380 | Oct 2010 → Jul 2014 | chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01204164 | Aug 2010 → Mar 2016 | acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, myelodysplastic syndrome, plasma cell myeloma | Tragara Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00603447 | May 2008 → May 2013 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00150462 | Sep 2005 → Oct 2009 | Hodgkins lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1/242 trials | ||||||
| Phase 1/2 | NCT07479979 | Jul 2026 → Jul 2027 expected | plasma cell myeloma | Natalie Callander | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06055075 | Dec 2023 → Jul 2025 | refractory plasma cell neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT05434689 | Jan 2023 → Aug 2028 expected | plasma cell myeloma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05017545 | Dec 2021 → Feb 2027 expected | anti-HLA hyperimmunization | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05060627 | Dec 2021 → Oct 2024 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04764942 | May 2021 → May 2026 overdue | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03795597 | May 2019 → Nov 2022 | plasma cell myeloma | Loyola University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02545907 | Sep 2017 → Sep 2019 | amyloidosis | University College, London | Completed | No outcome recorded |
| Phase 1/2 | NCT02802163 | Jun 2017 → Sep 2020 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02867618 | Oct 2016 → Jun 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma | Columbia University | Terminated | No outcome recorded |
| Phase 1/2 | NCT02773030 | Oct 2016 → May 2024 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02937571 | Oct 2016 → Oct 2024 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03141203 | Jul 2015 → Aug 2020 | peripheral T-cell lymphoma, not otherwise specified | University of Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT02073097 | Jan 2015 → Jul 2021 | diffuse large B-cell lymphoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02341014 | Jan 2015 → Jan 2023 | T-cell non-Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02145403 | Oct 2014 → Nov 2018 | graft versus host disease, hematopoietic and lymphoid cell neoplasm | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02204241 | Jun 2014 → Jun 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02185820 | Jun 2014 → Jul 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02056756 | Apr 2014 → Sep 2015 | plasma cell myeloma | Stichting European Myeloma Network | Completed | No outcome recorded |
| Phase 1/2 | NCT01962792 | Dec 2013 → Mar 2019 | plasma cell myeloma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT01987232 | Nov 2013 → Aug 2016 | small cell lung carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT02002598 | Nov 2013 → Mar 2019 | plasma cell myeloma | Suzanne Lentzsch, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT01941316 | Nov 2013 → Dec 2018 | non-small cell lung carcinoma, small cell lung carcinoma | Cancer Research and Biostatistics Clinical Trials Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT01842308 | Jun 2013 → Oct 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01792102 | Apr 2013 → Dec 2018 | plasma cell myeloma | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01857115 | Apr → Nov 2013 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01665794 | Aug 2012 → Nov 2025 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 1/2 | NCT01677858 | Jul 2012 → Jul 2016 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT01658904 | Jul 2012 → Feb 2014 | plasma cell leukemia, plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT01246063 | May 2012 → Dec 2017 | plasma cell myeloma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01690143 | May 2012 → Nov 2017 | plasma cell myeloma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 1/2 | NCT01496118 | Dec 2011 → Dec 2020 | plasma cell myeloma | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01464034 | Nov 2011 → Jul 2020 | plasma cell myeloma | Criterium, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01365559 | May 2011 → Jun 2014 | plasma cell myeloma | Oncotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01297764 | Apr 2011 → Jul 2026 overdue | plasma cell myeloma | Hackensack Meridian Health | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01279694 | Oct 2010 → Feb 2014 | plasma cell myeloma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01057225 | Mar 2010 → Mar 2014 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01029054 | Sep 2009 → Dec 2011 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00531284 | Sep 2007 → Oct 2014 | kidney cancer, non-small cell lung carcinoma, ovarian cancer, plasma cell myeloma +1 | Amgen | Completed | No outcome recorded |
| Phase 283 trials | ||||||
| Phase 2 | NCT07605416 | Jul 2026 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07652879 | Jun 2026 → Jan 2028 expected | POEMS syndrome | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07227311 | Apr 2026 → Aug 2030 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07348393 | Feb 2026 → Feb 2029 expected | refractory plasma cell neoplasm | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06627751 | May 2025 → May 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06158412 | Nov 2023 → Dec 2025 overdue | plasma cell myeloma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06140966 | Oct 2023 → Oct 2026 expected | plasma cell leukemia, plasma cell myeloma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT05789303 | May 2023 → Jul 2028 expected | plasma cell myeloma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT04933539 | Oct 2022 → Aug 2026 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05497804 | Sep 2022 → Feb 2026 overdue | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04850599 | Jun 2022 → Oct 2027 expected | plasma cell myeloma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04925193 | Nov 2021 → Aug 2024 overdue | plasma cell myeloma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04892446 | Nov 2021 → Apr 2024 | plasma cell myeloma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT05509374 | Oct 2021 → Jun 2024 | plasma cell myeloma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04263480 | Aug 2021 → May 2028 expected | Waldenstrom macroglobulinemia | Christian Buske | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04883242 | Jul 2021 → Dec 2026 expected | plasma cell myeloma | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04661137 | Mar 2021 → Feb 2027 | plasma cell myeloma | Hackensack Meridian Health | Suspended | No outcome recorded |
| Phase 2 | NCT04287855 | Aug 2020 → Apr 2025 | plasma cell myeloma | Poitiers University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04191616 | Aug 2020 → Nov 2022 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT04430894 | Jul 2020 → Jul 2022 overdue | plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04176718 | May 2020 → May 2027 expected | plasma cell myeloma | Andrew Yee, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04268498 | Feb 2020 → Feb 2027 expected | plasma cell myeloma | University of Miami | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04113018 | Jan 2020 → Jun 2023 overdue | plasma cell myeloma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03891355 | Sep 2019 → Dec 2020 | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | No outcome recorded |
| Phase 2 | NCT03606577 | Jul 2019 → Feb 2022 overdue | plasma cell myeloma | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03815279 | Jun 2019 → Jan 2024 overdue | smoldering plasma cell myeloma | Landspitali University Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03500445 | Feb 2019 → Jun 2026 overdue | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03756896 | Jan 2019 → Jun 2025 overdue | plasma cell myeloma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03673826 | Nov 2018 → Aug 2024 overdue | smoldering plasma cell myeloma | HOVON Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03512353 | Jul 2018 → Jan 2020 | refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT03556332 | Jul 2018 → Jul 2027 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03289299 | May 2018 → Sep 2023 overdue | smoldering plasma cell myeloma | International Myeloma Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04065789 | May 2018 → Aug 2021 | plasma cell myeloma | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03412565 | Apr 2018 → Aug 2020 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03314636 | Mar 2018 → Nov 2021 overdue | plasma cell myeloma | Oslo University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03224507 | Mar 2018 → May 2023 | plasma cell myeloma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03256045 | Feb 2018 → Feb 2021 | plasma cell myeloma | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT03336073 | Dec 2017 → Dec 2024 | plasma cell myeloma | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT03269552 | Dec 2017 → Dec 2018 | Waldenstrom macroglobulinemia, marginal zone lymphoma | University of Washington | Terminated | No outcome recorded |
| Phase 2 | NCT03290950 | Sep 2017 → May 2025 overdue | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03140943 | Sep 2017 → Jun 2019 | refractory plasma cell neoplasm | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT03104842 | Aug 2017 → May 2026 overdue | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03155100 | Aug 2017 → Aug 2023 | plasma cell myeloma | Raija Silvennoinen | Completed | No outcome recorded |
| Phase 2 | NCT02969837 | Jul 2017 → Oct 2021 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03104270 | Mar 2017 → Oct 2019 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02891811 | Mar 2017 → Mar 2024 | plasma cell myeloma | Study Group of Medical Tumour Therapy (AGMT) | Completed | No outcome recorded |
| Phase 2 | NCT02899052 | Jan 2017 → Jun 2027 expected | plasma cell myeloma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02597062 | Jul 2016 → Jun 2019 | plasma cell myeloma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT02491359 | Nov 2015 → Feb 2018 | chronic graft versus host disease | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02474927 | Nov 2015 → Nov 2020 | transplant rejection | John F. McDyer, MD | Completed | No outcome recorded |
| Phase 2 | NCT02318784 | Jul 2015 → May 2021 | neuroendocrine neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02315716 | Jun 2015 → Nov 2019 overdue | plasma cell myeloma | University College, London | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02415413 | May 2015 → Jul 2018 overdue | smoldering plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02203643 | Feb 2015 → Oct 2016 | plasma cell myeloma | Mario Boccadoro | Completed | No outcome recorded |
| Phase 2 | NCT02572492 | Jan 2015 → Apr 2018 | plasma cell myeloma | Henrik Gregersen | Unknown | No outcome recorded |
| Phase 2 | NCT02294357 | Dec 2014 → Sep 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT02217163 | Oct 2014 → Oct 2020 | plasma cell myeloma | Singapore General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02114502 | Sep 2014 → Sep 2018 | plasma cell myeloma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02042950 | Jul 2014 → Dec 2017 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT02128230 | Jun 2014 → Feb 2019 | plasma cell myeloma | University of Arkansas | Terminated | No outcome recorded |
| Phase 2 | NCT02047253 | Apr 2014 → Jun 2017 | castration-resistant prostate carcinoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02405364 | Feb 2014 → Nov 2019 | plasma cell myeloma | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2 | NCT02302495 | Jan 2014 → Jul 2016 | plasma cell myeloma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2 | NCT01989325 | Nov 2013 → Feb 2016 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01903811 | Oct 2013 → Nov 2017 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT01775930 | Oct 2013 → Jan 2019 | kidney cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02020941 | Sep 2013 → Jan 2016 | plasma cell myeloma | Attaya Suvannasankha | Terminated | No outcome recorded |
| Phase 2 | NCT01775553 | Sep 2013 → May 2016 | plasma cell myeloma | Ajai Chari | Completed | No outcome recorded |
| Phase 2 | NCT01969565 | Aug 2013 → Oct 2014 | plasma cell myeloma | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01812720 | Aug 2013 → Sep 2014 | plasma cell myeloma | Mayo Clinic | Withdrawn | No outcome recorded |
| Phase 2 | NCT01813227 | Apr 2013 → Sep 2014 | Waldenstrom macroglobulinemia | Hackensack Meridian Health | Completed | No outcome recorded |
| Phase 2 | NCT01816971 | Jan 2013 → Apr 2018 | plasma cell myeloma | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01572480 | May 2012 → Mar 2022 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01559935 | Apr 2012 → Jun 2016 overdue | plasma cell myeloma | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01470196 | Oct 2011 → Sep 2016 | Waldenstrom macroglobulinemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01402284 | Jul 2011 → Jul 2016 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01346787 | Jul 2011 → Oct 2012 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 2 | NCT01351623 | May 2011 → Jan 2016 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00884312 | Apr 2009 → May 2017 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00721734 | Nov 2008 → Nov 2012 | impaired renal function disease, plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00530816 | Sep 2007 → Jan 2013 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00511238 | Aug 2007 → Nov 2010 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06879379 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04513639 | Aug 2020 → Jun 2031 expected | plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 316 trials | ||||||
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT05572515 | Mar 2023 → Oct 2025 overdue | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05552976 | Jan 2023 → Jul 2026 overdue | refractory plasma cell neoplasm | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04096066 | Jul 2019 → Jan 2026 overdue | plasma cell myeloma | Fondazione EMN Italy Onlus | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03729804 | May 2019 → Dec 2026 expected | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03742297 | Oct 2018 → Jul 2023 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03029234 | Mar 2017 → Nov 2018 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT02659293 | Apr 2016 → Nov 2027 expected | plasma cell myeloma | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02412878 | Sep 2015 → Jun 2017 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01863550 | Dec 2013 → Dec 2026 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01818752 | Jul 2013 → Jul 2016 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01568866 | Jun 2012 → Nov 2014 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01302392 | Sep 2010 → Jul 2014 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01080391 | Jul 2010 → Jun 2014 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06409702 | Jun 2024 → Nov 2027 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 4 | NCT03934684 | Sep 2019 → Mar 2023 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT00999414 | Nov 2009 → Apr 2015 | plasma cell myeloma | University of Arkansas | No longer available | No outcome recorded |
| — | NCT01410500 | — | plasma cell myeloma | Amgen | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 45 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT07082270 Background | Apr 2026 → Feb 2028 | plasma cell myeloma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT06622005 Background | Apr 2025 → Apr 2027 expected | plasma cell myeloma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT04813653 Background | Apr 2021 → Mar 2025 | plasma cell myeloma, refractory plasma cell neoplasm | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT04163107 Background | Jan 2020 → Dec 2021 | plasma cell myeloma | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT03031730 Background | Jun 2018 → Jul 2024 | plasma cell myeloma, plasmacytoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT02148913 Comparator | Jun 2014 → Dec 2018 | plasma cell myeloma | Corewell Health West | Completed | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02036502 Background | Feb 2014 → Mar 2020 | plasma cell myeloma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07463807 Comparator | Jul → Aug 2026 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05199311 Background | May 2022 → Mar 2027 | plasma cell myeloma | Hackensack Meridian Health | Suspended | No outcome recorded |
| Phase 1/2 | NCT04822337 Background | May 2021 → Apr 2029 expected | plasma cell myeloma | Wake Forest University Health Sciences | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03989414 Background | Sep 2019 → Nov 2026 expected | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03773107 Background | Jan 2019 → Nov 2022 | plasma cell myeloma | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT06948084 Comparator | Aug 2026 → Feb 2028 expected | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06356571 Background | Mar 2025 → Jan 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT05896228 Background | Feb 2024 → Mar 2029 expected | plasma cell myeloma | Benjamin T Diamond, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05909826 Background | Jul 2023 → Jun 2027 expected | plasma cell myeloma | Dong-A University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05704049 Background | Apr 2023 → Dec 2025 overdue | refractory plasma cell neoplasm | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05669989 Background | Apr 2023 → Nov 2026 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04756401 Background | Dec 2022 → Sep 2024 overdue | plasma cell myeloma | Academic and Community Cancer Research United | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03871829 Background | May 2019 → Oct 2022 | plasma cell myeloma | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT03805178 Background | May 2019 → Aug 2020 | transplant rejection | Duke University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03004287 Background | Jul 2017 → Oct 2026 expected | plasma cell myeloma | University of Arkansas | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02756663 Background | Dec 2016 → Feb 2021 | plasma cell myeloma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02628704 Background | Dec 2015 → Jun 2017 | plasma cell myeloma | Karyopharm Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT02188368 Background | Jul 2014 → Oct 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07555938 Comparator | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07391657 Comparator | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06615479 Background | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06413498 Comparator | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06232707 Comparator | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT06152575 Comparator | Feb 2024 → Aug 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT05438043 Background | Dec 2022 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT04483739 Background | Sep 2020 → Jul 2025 overdue | plasma cell myeloma | European Myeloma Network B.V. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04288765 Background | Mar 2020 → Dec 2024 | plasma cell myeloma | Grupo Cooperativo de Hemopatías Malignas | Withdrawn | No outcome recorded |
| Phase 3 | NCT03859427 Comparator | May 2019 → Mar 2023 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT03948035 Background | Aug 2018 → Aug 2029 expected | plasma cell myeloma | Wuerzburg University Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03275285 Background | Oct 2017 → Jan 2022 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT03158688 Background | Jun 2017 → Jul 2019 | plasma cell myeloma | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01554852 Comparator | May 2010 → Dec 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03416374 Background | Feb 2018 → May 2021 | refractory plasma cell neoplasm | Takeda | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06793475 Background | Apr 2025 → Jun 2026 overdue | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Press releases naming this drug 50 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-05-22 | Regeneron Pharmaceuticals | Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma regeneron.com ↗ |
| 2021-12-01 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse amgen.com ↗ |
| 2021-03-31 | Sanofi | FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma sanofi.com ↗ |
| 2021-02-26 | Sanofi | Media Update: CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma sanofi.com ↗ |
| 2020-08-20 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens amgen.com ↗ |
| 2020-05-05 | Amgen | KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer amgen.com ↗ |
| 2019-12-10 | Amgen | Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting amgen.com ↗ |
| 2019-09-13 | Amgen | Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival amgen.com ↗ |
| 2019-09-12 | Amgen | Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗ |
| 2018-10-01 | Amgen | FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma amgen.com ↗ |
| 2018-08-27 | Amgen | Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone amgen.com ↗ |
| 2018-06-11 | Amgen | FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label amgen.com ↗ |
| 2018-06-01 | Amgen | Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma amgen.com ↗ |
| 2018-04-30 | Amgen | Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label amgen.com ↗ |
| 2018-01-30 | Amgen | Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label amgen.com ↗ |
| 2018-01-17 | Amgen | Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology amgen.com ↗ |
| 2018-01-17 | Amgen | FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label amgen.com ↗ |
| 2017-12-11 | Amgen | KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial amgen.com ↗ |
| 2017-10-23 | Amgen | Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients amgen.com ↗ |
| 2017-08-30 | Amgen | Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2017-08-30 | Amgen | FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS® (Carfilzomib) Label amgen.com ↗ |
| 2017-08-23 | Amgen | Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology amgen.com ↗ |
| 2017-07-14 | Amgen | Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS® (Carfilzomib) Label amgen.com ↗ |
| 2017-07-12 | Amgen | Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2017-03-03 | Amgen | Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop amgen.com ↗ |
| 2017-03-01 | Amgen | Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop amgen.com ↗ |
| 2017-02-28 | Amgen | Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients amgen.com ↗ |
| 2016-11-10 | Amgen | Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma amgen.com ↗ |
| 2016-09-27 | Amgen | Amgen Announces Top-Line Results From Phase 3 KYPROLIS® (Carfilzomib) CLARION Study In Newly Diagnosed Multiple Myeloma Patients amgen.com ↗ |
| 2016-07-03 | Amgen | European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients amgen.com ↗ |
| 2016-06-10 | Amgen | New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression amgen.com ↗ |
| 2016-06-06 | Amgen | New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen amgen.com ↗ |
| 2016-06-03 | Amgen | Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers amgen.com ↗ |
| 2016-05-27 | Amgen | Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis® (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma amgen.com ↗ |
| 2016-05-26 | Amgen | Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" amgen.com ↗ |
| 2016-01-21 | Amgen | FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma amgen.com ↗ |
| 2015-12-05 | Amgen | Pivotal Head-To-Head ENDEAVOR Study Results Published in The Lancet Oncology Demonstrate Superiority of Kyprolis® (carfilzomib) Combination Over Velcade® (bortezomib) Combination amgen.com ↗ |
| 2015-12-05 | Amgen | New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma amgen.com ↗ |
| 2015-12-05 | Amgen | Amgen Submits Application In Europe To Expand Indication Of Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-11-19 | Amgen | European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-09-23 | Amgen | Amgen To Present New Kyprolis® (carfilzomib) Data At 15th International Myeloma Workshop amgen.com ↗ |
| 2015-09-18 | Amgen | FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-07-24 | Amgen | FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-07-23 | Amgen | Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-05-31 | Amgen | Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma amgen.com ↗ |
| 2015-03-30 | Amgen | FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-03-02 | Amgen | Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-02-26 | Amgen | Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma amgen.com ↗ |
| 2015-01-27 | Amgen | Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma amgen.com ↗ |
| 2014-12-06 | Amgen | Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma amgen.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 242 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carfilzomib | “induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed...” NCT03224507 ↗240“Carfilzomib combined with cyclosporine and methotrexate for the prevention of graft-versus-host disease after allogeneic stem-cell transplantation from unrelated donors.” PMID 32873915 ↗ Sep 2020 “Carfilzomib is a selective PI that irreversibly binds the proteasome, eliciting antimyeloma activity through unfolded protein stress response and other mechanisms.” NCT07348393 ↗ “Proteasome inhibitor: Carfilzomib 27mg/m2 2 consecutive days per week x 3 weeks (20mg/m2 on day 1 and day 2 of cycle 1);” NCT06158412 ↗ “four 28-day cycles of carfilzomib (56 mg/m2 intravenously on days 1, 2, 8, 9, 15, and 16)” PMID 36529145 ↗ Dec 2022 “Induction = 8 cycles Carfilzomib on Day 1st, 8th and 15th Lenalidomide: Day 1 to 21” NCT04288765 ↗ “proteasome inhibitor (bortezomib or carfilzomib)” NCT02188368 ↗ “Carboplatin, Carfilzomib, Carmustine” NCT02788201 ↗ “Cabozantinib Carfilzomib Ceritinib” NCT02551718 ↗ “Carfilzomib (Kyprolis®)” NCT02128230 ↗ |
| Known as | CAR | “The main aim of this study is to assess the ORR with a new drug combination, carfilzomib (CAR) + elotuzumab (ELO) + dexamethasone (CAR-ELO-Dex).” NCT03155100 ↗ |
| Known as | Carfilzomib - Kyprolis | “Carfilzomib (Kyprolis®)” NCT02128230 ↗3“Carfilzomib (KYPROLIS®)” NCT05651932 ↗ “Carfilzomib - Kyprolis” NCT02148913 ↗ “Carfilzomib (Kyprolis)” NCT01297764 ↗ |
| Known as | Carfilzomib Injection | “Drug: Carfilzomib Injection” NCT04163107 ↗ |
| Known as | CFZ | “CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).” NCT02188368 ↗2“Carfilzomib (CFZ) is a newer proteasome inhibitor with increased activity and a safer toxicity profile than bortezomib in PCM.” NCT01658904 ↗ “Carfilzomib (CFZ) in combination with low-dose dexamethasone (Kd)” NCT03651128 ↗ |
| Known as | Kyprolis | “A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or...” NCT01962792 ↗4“KRdD = Kyprolis (Carfilzomib), Revlimid (Lenalidomide), dexamethasone, Darzalex (Daratumumab)” NCT03224507 ↗ “Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle” NCT05651932 ↗ “Carfilzomib 56 MG [Kyprolis]” NCT05509374 ↗ “carfilzomib (Kyprolis®)” NCT05060627 ↗ |
| Known as | Kyprolis (carfilzomib) | “Kyprolis (carfilzomib)” NCT01554852 ↗ |
| Known as | Kyprolis (carfilzomib) for Injection | “Kyprolis® (carfilzomib) for Injection” NCT01980589 ↗6“Kyprolis® (carfilzomib) for Injection” NCT02303821 ↗ “Kyprolis® (carfilzomib) for Injection” NCT00511238 ↗ “Kyprolis® (carfilzomib) for Injection” NCT01949545 ↗ “Kyprolis® (carfilzomib) for Injection” NCT02412878 ↗ “Kyprolis® (carfilzomib) for Injection” NCT02335983 ↗ “Kyprolis® (carfilzomib) for Injection” NCT00530816 ↗ |
| Known as | NSC-758252 | ChEMBL registry synonym — accepted as the source's own label CHEMBL451887 ↗ |
| Known as | PR-171 | “Carfilzomib (formerly PR-171) is a tetrapeptide epoxyketone-based irreversible inhibitor of the 20S proteasome.” NCT03140943 ↗ |
| Action | Inhibit | “Carfilzomib is a proteasome inhibitor” NCT00150462 ↗ |
| Modality | Other / unclassified | “Carfilzomib is a type of drug called a proteasome inhibitor.” NCT02294357 ↗ |
| Route | Intravenous | “Administered as an IV bolus dose” NCT00150462 ↗ |